Long-term follow-up, complications and outcomes of Meso-Rex bypass for extrahepatic portal vein obstruction (EHPVO): a systematic review.

Dig Liver DisJul 27, 2026 (epub)

Pietro Riva, Luca Pio, Angelo Zarfati et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated long-term outcomes of Meso-Rex Bypass (MRB) in pediatric patients with extrahepatic portal vein obstruction (EHPVO). Analyzing 40 studies with 1403 MRB operations, the review found shunt patency in 87% of cases. The median follow-up was 30 months, revealing significant improvements in hematologic parameters and spleen size.

Key findings

  • Shunt patency was achieved in 87% (1229/1403) of MRB operations.
  • Recurrent gastrointestinal bleeding occurred in 13% (92/730) of patients.
  • All studies evaluating portal pressures reported decreases, though mean postoperative values remained above 10 mmHg.
  • Five patients (0.3%) died, with one death related to MRB.

Why it matters

Understanding the long-term outcomes of MRB in pediatric EHPVO is crucial for clinicians managing this condition, as it highlights the procedure's effectiveness in improving hematologic parameters and reducing complications.

Source

Published in Dig Liver Dis. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.